Stock Research for PGNX


Featured Broker: Ally Invest

Get the due diligence for another stock.


PGNX Stock Chart & Research Data

The PGNX chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the PGNX chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


PGNX Due diligence Resources & Stock Charts

The PGNX stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View PGNX Detailed Price Forecast - CNN Money CNN View PGNX Detailed Summary - Google Finance
Yahoo View PGNX Detailed Summary - Yahoo! Finance Zacks View PGNX Stock Research & Analysis -

Stock Analysis

TradeIdeas View PGNX Trends & Analysis - Trade-Ideas Barrons View PGNX Major Holders - Barrons
NASDAQ View PGNX Call Transcripts - NASDAQ Seeking View PGNX Breaking News & Analysis - Seeking Alpha
Spotlight View PGNX Annual Report - OTC Report View PGNX OTC Short Report -
TradeKing View PGNX Fundamentals - TradeKing Charts View PGNX SEC Filings - Bar Chart
WSJ View Historical Prices for PGNX - The WSJ Morningstar View Performance/Total Return for PGNX - Morningstar
MarketWatch View the Analyst Estimates for PGNX - MarketWatch CNBC View the Earnings History for PGNX - CNBC
StockMarketWatch View the PGNX Earnings - StockMarketWatch MacroAxis View PGNX Buy or Sell Recommendations - MacroAxis
Bullish View the PGNX Bullish Patterns - American Bulls Short Pains View PGNX Short Pain Metrics -

Social Media Mentions

StockTwits View PGNX Stock Mentions - StockTwits PennyStocks View PGNX Stock Mentions - PennyStockTweets
Twitter View PGNX Stock Mentions - Twitter Invest Hub View PGNX Investment Forum News - Investor Hub
Yahoo View PGNX Stock Mentions - Yahoo! Message Board Seeking Alpha View PGNX Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for PGNX - Insider Cow View Insider Transactions for PGNX - Insider Cow
CNBC View PGNX Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for PGNX - OTC Markets
Yahoo View Insider Transactions for PGNX - Yahoo! Finance NASDAQ View Institutional Holdings for PGNX - NASDAQ

Stock Charts

FinViz View PGNX Stock Insight & Charts - StockCharts View PGNX Investment Charts -
BarChart View PGNX Stock Overview & Charts - BarChart Trading View View PGNX User Generated Charts - Trading View

Latest Financial News for PGNX

Steven Cohen Storms Into Progenics Pharmaceuticals
Posted on Thursday January 03, 2019

Point72 asset manager adds cancer-treating company to pile of health care positions

Progenics and Curium Announce European Collaboration for Prostate Cancer Imaging Agent PyL™
Posted on Wednesday January 02, 2019

Progenics Pharmaceuticals, Inc. (PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, and Curium today announced an exclusive agreement to develop and commercialize PyL in Europe. PyL is Progenics’ PSMA-targeted small molecule PET/CT imaging agent designed to visualize prostate cancer currently in Phase 3 development.

Progenics Pharmaceuticals Expands Leadership Team with Appointment of Asha Das, M.D. as Chief Medical Officer 
Posted on Wednesday January 02, 2019

Progenics Pharmaceuticals, Inc. (PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, today announced the appointment of Asha Das, M.D. to the newly created role of Chief Medical Officer. Dr. Das brings 13 years of drug development experience, including leading activities related to the approval and launch of Avastin® in multiple indications at Genentech, as well as a decade of clinical practice and academic expertise in neurology and neuro-oncology. “Asha is a talented clinician and a proven oncology drug development leader,” stated Mark Baker, CEO of Progenics. “Her experience developing and executing registrational studies will be invaluable to Progenics as we advance our portfolio of PSMA-targeted imaging and therapeutic agents and look to developing new indications for AZEDRA.

Here Are 3 Small-Cap Names for Biotech Investors to Consider
Posted on Wednesday December 12, 2018

Today, we look at a slightly riskier part of the sector in promising small caps that should be able to reach profitability with little to no additional funding needs. Revenues should more than double this year to over $140 million as the genetic test market continues to expand rapidly and Invitae garners market share. The company is doing a good job lessening its cash burn every quarter and is on the path to reach profitability late in 2019.

Stock Market & Investing Books

Enter a stock symbol to view the stock details.